Stifel analyst, Paul Matteis, reiterated his Buy rating on shares of GW Pharma (NASDAQ: GWPH) after attending a dinner with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE